---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-070166"
form_type: "8-K"
ticker: "IOBTQ"
cik: "0001865494"
company_name: "IO Biotech, Inc."
filed_at: "2023-03-14T23:59:59+00:00"
generated_at: "2026-06-18T03:57:04.837948+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# IO Biotech reports 2022 net loss of $71.5M; cash runway through Q3 2024

## Summary
- Net loss $71.5M for 2022 vs $67.9M for 2021; Q4 net loss $20.1M vs $21.3M.
- R&D expenses $47.0M (+56% YoY) driven by Phase 3 trial execution; G&A $24.4M (+120%).
- Cash and equivalents $142.6M at Dec 31, 2022, down from $211.5M; expects runway through Q3 2024.
- Phase 3 advanced melanoma trial (IOB-013) targets 75% enrollment by mid-2023; interim ORR analysis could enable accelerated BLA.
- Appointed Amy Sullivan CFO (Oct 2022) and Devin Smith GC (Jan 2023).

## SEC filing metadata
- accession: 0001193125-23-070166
- form_type: 8-K
- ticker: IOBTQ
- cik: 0001865494
- company_name: IO Biotech, Inc.
- filed_at: 2023-03-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1865494/000119312523070166/0001193125-23-070166-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1865494/000119312523070166/d464597d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-070166
- JSON: https://secwatch.observer/filing/0001193125-23-070166.json
- Plain text: https://secwatch.observer/filing/0001193125-23-070166.txt

## Key facts
- Earnings Releases
  IO Biotech, Inc. reported the year ended December 31, 2022 results: net income $71.5 million.
  - Period: the year ended December 31, 2022
  - Net income: $71.5 million
  - Result: reported results
  source text: Net loss for the year ended December 31, 2022, was $71.5 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1865494/000119312523070166/0001193125-23-070166-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.